FSA Group analysis reveals negative $4.84 fair value despite operational improvements, with 15% probability of positive equity value given structural debt overhang.
View noteFletcher Building trades at $2.84 vs fair value $5.56, offering 96% upside through construction cycle recovery and strategic portfolio optimization.
View noteNova Eye Medical: BUY rating, A$0.48 fair value vs A$0.14 current price (243% upside). Pre-profit MIGS specialist targeting H1FY26 breakeven with 25% revenue growth.
View noteHOLD rating with fair value $0.133 vs current $0.150. Market leader in ANZ adventure tourism with 25% share, EBITDA margins at 14.7%, facing climate and competitive headwinds.
View noteSTRONG SELL rating with 84% downside to $2.20 fair value. EBITDA margins compressing from 26.4% peak as competition intensifies.
View notePayment processor trading at 42% discount to peers. Fair value $1.60 vs current $1.07. EBITDA margins recovering from 16.5% toward 26% through transformation programme.
View noteHOLD rating with $0.56 fair value vs $0.57 current price. Market leader in seniors' rental (18% share, 98% occupancy) executing risky all-age expansion. 35% execution failure probability creates binary outcomes.
View noteMarket leader trading at 48% discount to peers despite regulatory moats. Fair value $5.02 vs current $4.18 with 20% upside potential.
View noteSELL rating with fair value $4.71 vs current $7.42. Office REIT facing structural headwinds from hybrid working, 64% downside risk.
View noteIndustrial cooling manufacturer trading 58% above $2.65 fair value with deteriorating competitive moat, value-destructive ROIC of 7.5% vs 10.5% WACC, and technology disruption risks.
View noteInfrastructure monopoly trading at $4.77 vs $3.11 fair value. 6.0x leverage, 2031 regulatory renewal risk, 91% DCF downside. Quality score 5.1/10.
View noteCyclopharm trades at $0.99 vs $1.18 fair value with 85% global market share in lung imaging, 29% revenue CAGR projected through US expansion
View note